News and views
June 2016 Br J Cardiol 2016;23:51
NICE go-ahead for sacubitril/valsartan
The National Institute for Health and Care Excellence (NICE) has issued Technical Appraisal Guidance for sacubitril/valsartan (Entresto™, Novartis Pharmaceuticals). The drug has been approved for use within the NHS for the treatment of adults with symptomatic chronic heart failure with New York Heart Association class II to IV symptoms, a left ventricular ejection fraction of 35% or less, and who are also taking a stable dose of angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers....
June 2016 Br J Cardiol 2016;23:56
Correspondence: Nicorandil, antithrombotic drugs, and non-variceal upper gastrointestinal bleeding
Dear Sirs,...
April 2016 Br J Cardiol 2016;23:(1) Online First
Update from the 8th BSH Day for Revalidation and Training
A wide array of investigations is available to the heart failure specialist. Their proper utilisation requires knowledge of their indications, and proficiency in interpretation. This was the focus of the second morning session, entitled “Different tests”, of the 8th British Society for Heart Failure (BSH) Training and Revalidation Day. Held on 3rd March 2016, at the Golden Jubilee National Hospital, Clydebank, this session included excellent presentations on cardiopulmonary exercise testing (CPET), cardiac catheterisation in heart failure, assessment of haemodynamics using echocardiography, and the use of cardiac CT in heart failure. Dr Simon Beggs reports on some of the highlights from a lively and thought-provoking day....
March 2016 Br J Cardiol 2016;23:9
NICE quality standard on acute heart failure
The National Institute for Health and Care Excellence (NICE) has published a new quality standard in acute heart failure (QS103) to cover the care of adults (over 18 years) who have a diagnosis of acute heart failure or are being investigated for acute heart failure. ...
March 2016 Br J Cardiol 2016;23:9
Confusing NICE guidance on PCSK9 inhibitors
The cholesterol charity, HEART UK, has questioned NICE’s decisions on the new PCSK9 inhibitors evolocumab (Repatha®, Amgen) and alirocumab (Pralulent®, Sanofi Regeneron), which were approved in Europe in May 2015 and in the USA in August 2015 for patients who are unable to control their cholesterol with current therapies. ...
March 2016 Br J Cardiol 2016;23:15
Book review: Hypertension, 2nd edition
Editors: Nadar S, Lip GY ...
March 2016 Br J Cardiol 2016;23:14
Correspondence: ‘You look dishevelled’ – MI in a cardiologist diagnosed by his secretary
Correspondence from the world of cardiology...
